IQVIA Holdings Inc. (IQV) EV/FCF Ratio: 11.54x
Is IQVIA Holdings Inc.’s EV/FCF ratio high or low?
IQVIA Holdings Inc.'s EV/FCF ratio of 11.54x is 58% below its 5-year average of 27.69x, near the low end of its 5-year range (10.34x–43.75x).
The EV/FCF ratio for IQVIA Holdings Inc. (IQV) is 11.54x as of Thursday, June 11, 2026. It is below its 12-month average by 39.88% (19.19x).
IQV EV/FCF Ratio Chart
IQV Average EV/FCF Ratio Chart
IQV Current vs Average EV/FCF Ratio Chart
IQV EV/FCF Ratio Metrics
EV/FCF RATIO
11.54x
EV/FCF RATIO AVG TTM
19.19x
EV/FCF RATIO AVG 3Y
27.03x
EV/FCF RATIO AVG 5Y
27.69x
EV/FCF RATIO AVG 10Y
35.11x
EV/FCF RATIO AVG 15Y
33.81x
EV/FCF RATIO AVG 20Y
33.81x
CURRENT VS TTM AVG
-39.88%
CURRENT VS 3Y AVG
-57.30%
CURRENT VS 5Y AVG
-58.32%
CURRENT VS 10Y AVG
-67.13%
CURRENT VS 15Y AVG
-65.87%
CURRENT VS 20Y AVG
-65.87%
IQV Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.08B | 11.54x | 19.19x | 27.03x | 27.69x |
| Medline Inc. (MDLN) | $30.90B | 26.55x | 27.74x | 27.74x | 27.74x |
| Biogen Inc. (BIIB) | $28.94B | 12.26x | 12.72x | 21.64x | 21.17x |
| DexCom, Inc. (DXCM) | $28.92B | 20.82x | 37.28x | 66.76x | 181.49x |
| Centene Corporation (CNC) | $32.26B | 4.33x | 9.68x | 24.78x | 19.04x |
| Veeva Systems Inc. (VEEV) | $26.73B | 48.97x | 29.32x | 32.91x | 38.27x |
| Zoetis Inc. (ZTS) | $34.27B | 19.58x | 28.10x | 41.99x | 48.24x |
| Waters Corporation (WAT) | $23.60B | 131.87x | 43.74x | 43.15x | 41.51x |
| Agilent Technologies, Inc. (A) | $37.17B | 30.99x | 34.61x | 30.04x | 33.46x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 31.58x | 33.77x | 33.51x | 38.37x |
Cash Flow Valuation Comparison
EV/FCF
11.5x
P/FCF
11.5x
FCF Yield
8.70%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
IQVIA Holdings Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The EV/FCF ratio for IQV stock is 11.54x.
- Is IQVIA Holdings Inc.'s EV/FCF ratio high or low?
- IQVIA Holdings Inc.'s EV/FCF ratio of 11.54x is 58% below its 5-year average of 27.69x, near the low end of its 5-year range (10.34x–43.75x).
- What is the TTM average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average EV/FCF ratio for IQV stock is 19.19x.
- What is the 3Y average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average EV/FCF ratio for IQV stock is 27.03x.
- What is the 5Y average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average EV/FCF ratio for IQV stock is 27.69x.
- What is the 10Y average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average EV/FCF ratio for IQV stock is 35.11x.
- What is the 15Y average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The 15Y average EV/FCF ratio for IQV stock is 33.81x.
- What is the 20Y average EV/FCF ratio for IQVIA Holdings Inc. (IQV)?
- The 20Y average EV/FCF ratio for IQV stock is 33.81x.
IQVIA Holdings Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-11 | 11.54x |
| 2026-06-10 | 11.62x |
| 2026-06-09 | 11.88x |
| 2026-06-08 | 11.72x |
| 2026-06-05 | 11.71x |
| 2026-06-04 | 11.92x |
| 2026-06-03 | 11.62x |
| 2026-06-02 | 11.53x |
| 2026-06-01 | 11.92x |
| 2026-05-29 | 11.63x |
| 2026-05-28 | 11.56x |
| 2026-05-27 | 10.57x |
| 2026-05-26 | 10.34x |
| 2026-05-22 | 10.72x |
| 2026-05-21 | 10.73x |
| 2026-05-20 | 10.95x |
| 2026-05-19 | 11.05x |
| 2026-05-18 | 11.03x |
| 2026-05-15 | 10.80x |
| 2026-05-14 | 10.89x |
| 2026-05-13 | 11.00x |
| 2026-05-12 | 11.17x |
| 2026-05-11 | 11.08x |
| 2026-05-08 | 11.40x |
| 2026-05-07 | 11.40x |
| 2026-05-06 | 11.26x |
| 2026-05-05 | 11.26x |
| 2026-05-04 | 16.88x |
| 2026-05-01 | 16.66x |
| 2026-04-30 | 16.70x |
| 2026-04-29 | 16.58x |
| 2026-04-28 | 16.74x |
| 2026-04-27 | 17.08x |
| 2026-04-24 | 16.97x |
| 2026-04-23 | 16.86x |
| 2026-04-22 | 17.87x |
| 2026-04-21 | 17.90x |
| 2026-04-20 | 17.98x |
| 2026-04-17 | 17.95x |
| 2026-04-16 | 17.64x |
| 2026-04-15 | 18.07x |
| 2026-04-14 | 17.87x |
| 2026-04-13 | 17.64x |
| 2026-04-10 | 17.32x |
| 2026-04-09 | 17.44x |
| 2026-04-08 | 17.68x |
| 2026-04-07 | 17.55x |
| 2026-04-06 | 17.56x |
| 2026-04-02 | 17.73x |
| 2026-04-01 | 17.67x |
| 2026-03-31 | 17.54x |
| 2026-03-30 | 17.24x |
| 2026-03-27 | 17.08x |
| 2026-03-26 | 17.47x |
| 2026-03-25 | 17.20x |
| 2026-03-24 | 17.24x |
| 2026-03-23 | 17.30x |
| 2026-03-20 | 17.23x |
| 2026-03-19 | 17.26x |
| 2026-03-18 | 17.30x |
| 2026-03-17 | 17.40x |
| 2026-03-16 | 17.15x |
| 2026-03-13 | 17.14x |
| 2026-03-12 | 17.02x |
| 2026-03-11 | 17.62x |
| 2026-03-10 | 17.57x |
| 2026-03-09 | 18.10x |
| 2026-03-06 | 17.82x |
| 2026-03-05 | 18.10x |
| 2026-03-04 | 18.05x |
| 2026-03-03 | 17.78x |
| 2026-03-02 | 17.80x |
| 2026-02-27 | 18.12x |
| 2026-02-26 | 17.55x |
| 2026-02-25 | 16.95x |
| 2026-02-24 | 17.15x |
| 2026-02-23 | 16.97x |
| 2026-02-20 | 17.20x |
| 2026-02-19 | 17.46x |
| 2026-02-18 | 17.58x |
| 2026-02-17 | 17.12x |
| 2026-02-13 | 15.92x |
| 2026-02-12 | 16.05x |
| 2026-02-11 | 16.59x |
| 2026-02-10 | 16.93x |
| 2026-02-09 | 17.60x |
| 2026-02-06 | 17.26x |
| 2026-02-05 | 16.84x |
| 2026-02-04 | 18.24x |
| 2026-02-03 | 18.32x |
| 2026-02-02 | 20.11x |
| 2026-01-30 | 20.04x |
| 2026-01-29 | 20.39x |
| 2026-01-28 | 20.66x |
| 2026-01-27 | 20.74x |
| 2026-01-26 | 20.64x |
| 2026-01-23 | 20.37x |
| 2026-01-22 | 20.61x |
| 2026-01-21 | 20.77x |
| 2026-01-20 | 20.27x |
| 2026-01-16 | 20.52x |
| 2026-01-15 | 20.76x |
| 2026-01-14 | 20.76x |
| 2026-01-13 | 20.78x |
| 2026-01-12 | 20.73x |
| 2026-01-09 | 20.83x |
| 2026-01-08 | 20.88x |
| 2026-01-07 | 20.95x |
| 2026-01-06 | 20.71x |
| 2026-01-05 | 20.32x |
| 2026-01-02 | 19.72x |
| 2025-12-31 | 19.73x |
| 2025-12-30 | 19.88x |
| 2025-12-29 | 19.84x |
| 2025-12-26 | 19.83x |
| 2025-12-24 | 19.77x |
| 2025-12-23 | 19.71x |
| 2025-12-22 | 19.66x |
| 2025-12-19 | 19.42x |
| 2025-12-18 | 19.54x |
| 2025-12-17 | 19.47x |
| 2025-12-16 | 19.48x |
| 2025-12-15 | 19.61x |
| 2025-12-12 | 19.52x |
| 2025-12-11 | 19.76x |
| 2025-12-10 | 19.56x |
| 2025-12-09 | 19.25x |
| 2025-12-08 | 19.61x |
| 2025-12-05 | 19.76x |
| 2025-12-04 | 19.69x |
| 2025-12-03 | 19.85x |
| 2025-12-02 | 19.74x |
| 2025-12-01 | 19.93x |
| 2025-11-28 | 20.03x |
| 2025-11-26 | 20.14x |
| 2025-11-25 | 20.15x |
| 2025-11-24 | 19.91x |
| 2025-11-21 | 19.69x |
| 2025-11-20 | 19.19x |
| 2025-11-19 | 19.21x |
| 2025-11-18 | 19.20x |
| 2025-11-17 | 19.12x |
| 2025-11-14 | 19.41x |
| 2025-11-13 | 19.61x |
| 2025-11-12 | 19.43x |
| 2025-11-11 | 19.28x |
| 2025-11-10 | 18.92x |
| 2025-11-07 | 18.75x |
| 2025-11-06 | 18.78x |
| 2025-11-05 | 18.73x |
| 2025-11-04 | 18.79x |
| 2025-11-03 | 18.98x |
| 2025-10-31 | 19.14x |
| 2025-10-30 | 19.15x |
| 2025-10-29 | 19.23x |
| 2025-10-28 | 19.25x |
| 2025-10-27 | 25.53x |
| 2025-10-24 | 25.80x |
| 2025-10-23 | 25.75x |
| 2025-10-22 | 25.57x |
| 2025-10-21 | 25.64x |
| 2025-10-20 | 25.07x |
| 2025-10-17 | 24.42x |
| 2025-10-16 | 24.53x |
| 2025-10-15 | 24.30x |
| 2025-10-14 | 24.44x |
| 2025-10-13 | 24.36x |
| 2025-10-10 | 23.87x |
| 2025-10-09 | 24.29x |
| 2025-10-08 | 24.08x |
| 2025-10-07 | 24.10x |
| 2025-10-06 | 24.46x |
| 2025-10-03 | 24.60x |
| 2025-10-02 | 24.40x |
| 2025-10-01 | 24.36x |
| 2025-09-30 | 23.16x |
| 2025-09-29 | 22.37x |
| 2025-09-26 | 22.27x |
| 2025-09-25 | 22.02x |
| 2025-09-24 | 22.41x |
| 2025-09-23 | 22.86x |
| 2025-09-22 | 22.98x |
| 2025-09-19 | 22.93x |
| 2025-09-18 | 23.19x |
| 2025-09-17 | 22.88x |
| 2025-09-16 | 22.89x |
| 2025-09-15 | 22.82x |
| 2025-09-12 | 22.93x |
| 2025-09-11 | 23.23x |
| 2025-09-10 | 22.64x |
| 2025-09-09 | 23.14x |
| 2025-09-08 | 22.97x |
| 2025-09-05 | 22.97x |
| 2025-09-04 | 22.66x |
| 2025-09-03 | 22.71x |
| 2025-09-02 | 22.63x |
| 2025-08-29 | 23.24x |
| 2025-08-28 | 23.06x |
| 2025-08-27 | 23.07x |
| 2025-08-26 | 22.98x |
| 2025-08-25 | 23.00x |
| 2025-08-22 | 23.27x |
| 2025-08-21 | 22.77x |
| 2025-08-20 | 23.34x |
| 2025-08-19 | 23.37x |
| 2025-08-18 | 23.39x |
| 2025-08-15 | 23.26x |
| 2025-08-14 | 23.12x |
| 2025-08-13 | 23.19x |
| 2025-08-12 | 22.82x |
| 2025-08-11 | 22.31x |
| 2025-08-08 | 22.29x |
| 2025-08-07 | 22.22x |
| 2025-08-06 | 22.09x |
| 2025-08-05 | 22.65x |
| 2025-08-04 | 22.54x |
| 2025-08-01 | 22.52x |
| 2025-07-31 | 22.81x |
| 2025-07-30 | 23.30x |
| 2025-07-29 | 23.56x |
| 2025-07-28 | 23.84x |
| 2025-07-25 | 23.96x |
| 2025-07-24 | 24.10x |
| 2025-07-23 | 23.53x |
| 2025-07-22 | 22.94x |
| 2025-07-21 | 18.94x |
| 2025-07-18 | 19.08x |
| 2025-07-17 | 19.29x |
| 2025-07-16 | 18.91x |
| 2025-07-15 | 18.83x |
| 2025-07-14 | 19.04x |
| 2025-07-11 | 19.25x |
| 2025-07-10 | 19.48x |
| 2025-07-09 | 19.19x |
| 2025-07-08 | 19.39x |
| 2025-07-07 | 19.23x |
| 2025-07-03 | 19.37x |
| 2025-07-02 | 19.41x |
| 2025-07-01 | 19.24x |
| 2025-06-30 | 18.83x |
| 2025-06-27 | 18.82x |
| 2025-06-26 | 18.87x |
| 2025-06-25 | 18.92x |
| 2025-06-24 | 18.91x |
| 2025-06-23 | 18.63x |
| 2025-06-20 | 18.59x |
| 2025-06-18 | 18.58x |
| 2025-06-17 | 18.54x |
| 2025-06-16 | 18.96x |
| 2025-06-13 | 18.77x |
| 2025-06-12 | 18.95x |
| 2025-06-11 | 18.93x |
| 2025-06-10 | 19.01x |
| 2025-06-09 | 18.55x |
| 2025-06-06 | 18.40x |
| 2025-06-05 | 17.99x |
| 2025-06-04 | 18.03x |
| 2025-06-03 | 17.61x |
| 2025-06-02 | 17.31x |
| 2025-05-30 | 17.41x |
Showing the most recent 260 of 3,293 data points. The chart above shows the full history.
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib